DoD Awards $93M Clinical Development Study to Resilience Government Services, Inc
Contract Overview
Contract Amount: $93,029,233 ($93.0M)
Contractor: Resilience Government Services, Inc.
Awarding Agency: Department of Defense
Start Date: 2022-01-04
End Date: 2025-12-30
Contract Duration: 1,456 days
Daily Burn Rate: $63.9K/day
Competition Type: NOT AVAILABLE FOR COMPETITION
Pricing Type: COST PLUS FIXED FEE
Sector: R&D
Official Description: CLINICAL DEVELOPMENT PHASE 2 STUDY
Place of Performance
Location: FREDERICK, FREDERICK County, MARYLAND, 21702
State: Maryland Government Spending
Plain-Language Summary
Department of Defense obligated $93.0 million to RESILIENCE GOVERNMENT SERVICES, INC. for work described as: CLINICAL DEVELOPMENT PHASE 2 STUDY Key points: 1. Contract awarded for a Phase 2 clinical development study. 2. The contract value is substantial at $93 million. 3. Resilience Government Services, Inc. is the sole awardee. 4. The contract falls under Research and Development (R&D) in Physical, Engineering, and Life Sciences. 5. The contract duration is nearly four years.
Value Assessment
Rating: questionable
The contract type is Cost Plus Fixed Fee, which can lead to cost overruns if not managed carefully. The benchmark for similar R&D contracts is difficult to ascertain without more specific details on the study's scope.
Cost Per Unit: N/A
Competition Analysis
Competition Level: sole-source
The contract was not available for competition, indicating a sole-source award. This limits price discovery and potentially leads to higher costs for taxpayers.
Taxpayer Impact: The lack of competition for a $93 million contract raises concerns about the best use of taxpayer funds.
Public Impact
Taxpayers may not be receiving the best value due to the sole-source nature of the award. The specific outcomes and benefits of this clinical development study are not detailed, impacting public understanding of the investment. The long duration of the contract suggests a complex and potentially costly research endeavor.
Waste & Efficiency Indicators
Waste Risk Score: 50 / 10
Warning Flags
- Sole-source award
- Cost Plus Fixed Fee contract type
- Lack of public detail on study objectives
Positive Signals
- Supports critical R&D in life sciences
- Long-term commitment to a specific project
Sector Analysis
This contract falls within the Research and Development sector, specifically focusing on physical, engineering, and life sciences. Spending in this area is crucial for innovation but requires careful oversight to ensure value.
Small Business Impact
There is no indication that small businesses were involved in this contract, either as prime contractors or subcontractors.
Oversight & Accountability
The sole-source nature of this award warrants close oversight from the Department of the Army to ensure the contractor is meeting all milestones and that costs are justified.
Related Government Programs
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Department of Defense Contracting
- Department of the Army Programs
Risk Flags
- Sole-source award limits competition and price discovery.
- Cost Plus Fixed Fee contract type carries inherent risk of cost overruns.
- Lack of detailed public information on study objectives and expected outcomes.
- Potential for reduced value for taxpayer money due to non-competitive award.
Tags
research-and-development-in-the-physical, department-of-defense, md, delivery-order, 10m-plus
Frequently Asked Questions
What is this federal contract paying for?
Department of Defense awarded $93.0 million to RESILIENCE GOVERNMENT SERVICES, INC.. CLINICAL DEVELOPMENT PHASE 2 STUDY
Who is the contractor on this award?
The obligated recipient is RESILIENCE GOVERNMENT SERVICES, INC..
Which agency awarded this contract?
Awarding agency: Department of Defense (Department of the Army).
What is the total obligated amount?
The obligated amount is $93.0 million.
What is the period of performance?
Start: 2022-01-04. End: 2025-12-30.
What specific research objectives does this Phase 2 clinical development study aim to achieve, and how do they align with national priorities?
The provided data does not specify the research objectives of the Phase 2 clinical development study. Understanding the specific goals is crucial for assessing the scientific merit and potential impact of the $93 million investment. Alignment with national priorities, such as public health or defense-related medical advancements, would further justify the expenditure.
What justification was provided for awarding this contract on a sole-source basis, and were alternative competitive strategies considered?
The data states the contract was 'NOT AVAILABLE FOR COMPETITION,' implying a sole-source award. A thorough review would require understanding the specific justification for this determination. Typically, sole-source awards are made when only one responsible source can provide the required supplies or services, or in cases of urgent need. The absence of competition raises concerns about potential overpricing and limits the government's ability to secure the best possible value.
How will the effectiveness and value for money of this Cost Plus Fixed Fee contract be measured and ensured over its nearly four-year duration?
The effectiveness and value of a Cost Plus Fixed Fee contract are typically managed through rigorous oversight, milestone tracking, and performance metrics. For this $93 million award, the Department of the Army must establish clear performance standards and regularly audit costs to ensure they are reasonable and allocable to the contract. Regular reviews of progress against the clinical development plan are essential to confirm the study remains on track and delivers anticipated results.
Industry Classification
NAICS: Professional, Scientific, and Technical Services › Scientific Research and Development Services › Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Product/Service Code: RESEARCH AND DEVELOPMENT › N – Health R&D Services
Competition & Pricing
Extent Competed: NOT AVAILABLE FOR COMPETITION
Solicitation Procedures: ONLY ONE SOURCE
Solicitation ID: W911SR22R0040
Pricing Type: COST PLUS FIXED FEE (U)
Evaluated Preference: NONE
Contractor Details
Address: 13200 NW NANO CT, ALACHUA, FL, 32615
Business Categories: Category Business, Corporate Entity Not Tax Exempt, Manufacturer of Goods, Small Business, Special Designations, U.S.-Owned Business
Financial Breakdown
Contract Ceiling: $107,935,344
Exercised Options: $107,935,344
Current Obligation: $93,029,233
Contract Characteristics
Commercial Item: COMMERCIAL PRODUCTS/SERVICES PROCEDURES NOT USED
Cost or Pricing Data: NO
Parent Contract
Parent Award PIID: W911SR22D0009
IDV Type: IDC
Timeline
Start Date: 2022-01-04
Current End Date: 2025-12-30
Potential End Date: 2025-12-30 00:00:00
Last Modified: 2026-01-14
More Contracts from Resilience Government Services, Inc.
- Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) Capability — $276.8M (Department of Defense)
- Fill and Finish Capacity — $92.0M (Department of Defense)
- TO Make an Award Under Hhs-Nih-Niaid-Baa2018 — $15.1M (Department of Health and Human Services)
- Biomedical (basic) — $14.9M (Department of Health and Human Services)
View all Resilience Government Services, Inc. federal contracts →
Other Department of Defense Contracts
- Federal Contract — $51.3B (Humana Government Business Inc)
- Lrip LOT 12 Advance Acquisition Contract — $35.1B (Lockheed Martin Corporation)
- SSN 802 and 803 Long Lead Time Material — $34.7B (Electric Boat Corporation)
- 200204!008532!1700!AF600 !naval AIR Systems Command !N0001902C3002 !A!N! !N! !20011026!20120430!008016958!008016958!834951691!n!lockheed Martin Corporation !lockheed Blvd !fort Worth !tx!76108!27000!439!48!fort Worth !tarrant !texas !+000026000000!n!n!018981928201!ac15!rdte/Aircraft-Eng/Manuf Develop !a1a!airframes and Spares !2ama!jast/Jsf !336411!E! !3! ! ! ! ! !99990909!B! ! !A! !a!n!r!2!002!n!1a!a!n!z! ! !N!C!N! ! ! !a!a!a!a!000!a!c!n! ! ! !Y! !N00019!0001! — $34.2B (Lockheed Martin Corporation)
- KC-X Modernization Program — $32.0B (THE Boeing Company)